- Home
- TBLA vs GYRE Comparison
TBLA vs GYRE Comparison
Compare TBLA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLA
- GYRE
- Stock Information
- Founded
- TBLA 2007
- GYRE 2002
- Country
- TBLA United States
- GYRE United States
- Employees
- TBLA N/A
- GYRE N/A
- Industry
- TBLA Computer Software: Programming Data Processing
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- TBLA Technology
- GYRE Health Care
- Exchange
- TBLA Nasdaq
- GYRE Nasdaq
- Market Cap
- TBLA 976.2M
- GYRE 897.1M
- IPO Year
- TBLA N/A
- GYRE N/A
- Fundamental
- Price
- TBLA $3.20
- GYRE $7.23
- Analyst Decision
- TBLA Strong Buy
- GYRE Strong Buy
- Analyst Count
- TBLA 5
- GYRE 1
- Target Price
- TBLA $4.50
- GYRE $18.00
- AVG Volume (30 Days)
- TBLA 1.2M
- GYRE 89.9K
- Earning Date
- TBLA 11-06-2025
- GYRE 11-12-2025
- Dividend Yield
- TBLA N/A
- GYRE N/A
- EPS Growth
- TBLA N/A
- GYRE N/A
- EPS
- TBLA 0.04
- GYRE 0.02
- Revenue
- TBLA $1,817,019,000.00
- GYRE $102,189,000.00
- Revenue This Year
- TBLA $8.37
- GYRE $16.80
- Revenue Next Year
- TBLA $4.65
- GYRE $50.29
- P/E Ratio
- TBLA $78.41
- GYRE $424.69
- Revenue Growth
- TBLA 12.01
- GYRE N/A
- 52 Week Low
- TBLA $2.50
- GYRE $6.11
- 52 Week High
- TBLA $4.30
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- TBLA 33.27
- GYRE 42.70
- Support Level
- TBLA $3.18
- GYRE $7.20
- Resistance Level
- TBLA $3.60
- GYRE $7.44
- Average True Range (ATR)
- TBLA 0.08
- GYRE 0.25
- MACD
- TBLA -0.04
- GYRE -0.02
- Stochastic Oscillator
- TBLA 4.76
- GYRE 12.41
About TBLA Taboola.com Ltd.
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, United States, Germany, Rest of the world. It generates the majority of its revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.